CS
CNTA

Candriam SCA’s Centessa Pharmaceuticals CNTA Stock Holding History

Candriam SCA’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Sell
36,254
-359,369
-91% -$9.19M 0.01% 569
2025
Q4 		$9.89M Buy
395,623
+52,416
+15% +$1.33M 0.05% 270
2025
Q3 		$8.32M Sell
343,207
-4,392
-1% -$78.1K 0.04% 298
2025
Q2 		$4.57M Buy
+347,599
New +$4.4M 0.03% 368

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Candriam SCA's CNTA Position: Q1 2026 in Review

Candriam SCA reduced its Centessa Pharmaceuticals (CNTA) stake by 91% in Q1 2026, selling an estimated $9.19M and leaving 36,254 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #569.

Candriam SCA first reported a position in CNTA in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.89M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Candriam SCA held 36,254 shares of Centessa Pharmaceuticals worth $1.44M as of Q1 2026.
  • Candriam SCA sold 359,369 Centessa Pharmaceuticals shares in Q1 2026, an estimated $9.19M.
  • Centessa Pharmaceuticals made up 0.01% of Candriam SCA's portfolio in Q1 2026, its #569 holding.
  • Candriam SCA first reported a position in Centessa Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Candriam SCA's Centessa Pharmaceuticals position peaked at $9.89M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.